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a  b  s  t  r  a  c  t
Uliginosin  B  is  a  natural  phloroglucinol  derivative,  obtained  from  Hypericum  species  native  to  South
America.  Previous  studies  have  shown  that  uliginosin  B  presents  antidepressant-like  and  antinociceptive
effects.  Although  its  mechanism  of  action  is  still  not  completely  elucidated,  it is  known  that it involves  the
activation  of monoaminergic  neurotransmission.  The  aim  of  the current  study  was  to further  investigate
the  antinociceptive  mechanism  of action  of  uliginosin  B by  combining  it with  different  drugs  used  for
treating  pain  in  clinical  practice.  The  intraperitoneal  administration  of uliginosin  B, morphine,  amitripty-
line  and  clonidine,  alone  or in mixture,  produced  a dose-dependent  antinociceptive  effect in the  hot-plateurved isobologram
orphine synergism
nalgesia adjuvant
assay  in mice.  The  effect  of the  mixtures  of  drugs  was  studied  using  an  adapted  isobologram  analysis  at
the  effect  level  of 50%  of  the  maximal  effect  observed.  The  analysis  showed  that  the  interactions  between
uliginosin  B and  morphine  was  synergistic,  while  the interactions  between  uliginosin  B and  amitripty-
line  or  clonidine  were  additive.  These  ﬁndings  point  to  uliginosin  B  as  a potential  adjuvant  for  pain
pharmacotherapy,  especially  for opioid  analgesia.
© 2014  Elsevier  GmbH.  All  rights  reserved.ntroduction
Pain is a direct or indirect common consequence of several dis-
ases. The pharmacological treatment options are extensive and
nclude opioid drugs, non-opioid analgesics (e.g. non-steroidal anti-
nﬂammatory), other classes of drugs (e.g. tricyclic antidepressants
nd anticonvulsants) and adjuvants (e.g. caffeine and clonidine).
he choice of treatment is based primarily on the clinical status.
owever, the patients with pain, specially moderate to severe, are
ften under-treated due to lack of effective drugs and/or high rates
f adverse effects (Brunton et al., 2007).
Medicinal plants inspired the development of important drugs
sed in the treatment of pain (such as morphine, acetylsalicylic acid
nd colchicine) and may  still be expected to contribute to the search
or new therapeutic strategies as well as new molecular patterns
ith antinociceptive activity due to chemical diversity (Newman
nd Cragg, 2012; Phillipson, 2007).
∗ Corresponding author. Tel.: +55 51 33085455; fax: +55 51 33085437.
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944-7113/© 2014 Elsevier GmbH. All rights reserved.Previous studies performed by our group have shown that ulig-
inosin B (Fig. 1), a dimeric phloroglucinol derivative occurring in
Hypericum species native to South America (Ccana-Ccapatinta et al.,
2014), presents antidepressant-like, antinociceptive and ataxic
effects in rodents, depending on the dose range (Stein et al., 2012;
Stolz et al., 2012). These effects seem to be at least in part linked
to its ability to inhibit neuronal monoamine reuptake (Stein et al.,
2012) with consequent activation of dopamine receptors and indi-
rect stimulation of opioid system (Stolz et al., 2012). However,
uliginosin B does not bind to the monoaminergic sites on neuronal
carriers indicating that it acts differently from the classical antide-
pressants (Stein et al., 2012). Moreover, uliginosin B does not bind
to opioid and dopaminergic receptors and does not stimulate the G
protein coupled to these receptors (Stolz et al., 2012).
An alternative to enlarge the pharmacological spectrum is
the combination of substances, frequently evaluated through
the isobolographic analysis (Tallarida, 2006). The isobolographic
analysis is a strategy that allows to investigate the pharma-
codynamic and/or pharmacokinetic interaction between two  or
more substances as well as to study the mechanism of action of
these substances (Tallarida, 2007; Wagner and Ulrich-Merzenich,
2009).
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where Bi is the equi-effective dose for the drug B alone (morphine,Fig. 1. Uliginosin B structure.
Based on this context, the aim of this study was  to further
nvestigate the antinociceptive mechanism of action of uliginosin B
hrough the combination with different drugs used for treating pain
n clinical practice, namely morphine (opioid analgesic), amitripty-
ine (monoamine uptake inhibitor) and clonidine (2-adrenergic
nd imidazoline receptor agonist) in the hot-plate assay, in mice.
aterial and methods
liginosin B preparation
Uliginosin B was isolated from aerial parts of Hypericum polyan-
hemum Klotzsch ex Reichardt (Guttiferare). The vegetal material
as harvested during ﬂowering, in Cac¸ apava do Sul (30◦31′S;
3◦27′W),  Rio Grande do Sul state, Brazil, in October 2008. A
oucher specimen was identiﬁed by Dr. Sérgio Bordignon (UNI-
ASALLE, Brazil) and was deposited in the herbarium of the
niversidade Federal do Rio Grande do Sul – ICN H. polyanthemum,
ordignon et al. 175915. Plant collection was authorized by Con-
elho de Gestão do Patrimônio Genético and Instituto Brasileiro do
eio Ambiente – Number 003/2008, Protocol 02000.001717/2008
 60.
The n-hexane extract of aerial parts of H. polyanthemum was
btained by maceration, as described elsewhere (Stein et al., 2012;
tolz et al., 2012). Uliginosin B was isolated according to Stolz
t al. (2012) and its purity was conﬁrmed through HPLC analysis
oupled to an ultra-violet detector by two distinct methods (Ccana-
capatinta et al., 2014; Nunes et al., 2009) presenting the peak
rea greater than 94%; HRESIMS m/z  499.2320 [M + H]+ (predicted
or C28H35O8: 499.2332). Uliginosin B was structurally character-
zed by 1H and 13C NMR  spectra (60 MHz) without presenting any
nterfering signal, ensuring the purity of uliginosin B (Parker and
ohnson, 1968; Rocha et al., 1995; Taylor and Brooker, 1969).
hemicals and drugs
Dichloromethane, n-hexane and ethyl acetate were purchased
rom F. Maia® (São Paulo, Brazil); acetonitrile HPLC, methanol HPLC
nd deuterochloroform were purchased from Merck® (Darmstadt,
ermany); amitriptyline chloride and clonidine chloride were pur-
hased from Sigma-Aldrich, Co® (St. Louis, USA); morphine sulfate
nd polysorbate 80 were purchased from Cristalia® (São Paulo, SP,
razil) and Merck® (Darmstadt, Germany), respectively. All drugs
ere dissolved in saline (0.9% NaCl) and uliginosin B was suspended
n saline with an additional 2% polysorbate 80. All solutions were
repared freshly on the test day and administered by intraperi-
oneal route (i.p.) at 1 ml/100 g body weight.
nimals
Adult male CF1 mice (25 – 35 g) were purchased from Fundac¸ ão
stadual de Produc¸ ão e Pesquisa em Saúde (Brazil) colony. Six
nimals were housed per plastic cage (L: 28 cm,  W:  17 cm,  H:
3 cm)  under a 12 h light/dark cycle (lights on at 7:00 h) at con-
tant temperature (23 ± 1 ◦C) with free access to standard certiﬁed
odent diet (Nuvilab CR-1®) and tap water. All experiments weree 21 (2014) 1684–1688 1685
approved by a local Ethics Committee of Animal Use (UFRGS,
number 21060/2011) and were in compliance with Brazilian law
(Brasil, 2008, 2013a,b) and Council for International Organization
of Medical Sciences International guiding principles for biomedical
research involving animals (Bankowski and Howard-Jones, 1985).
Experimental design and isobolographic analysis
The individual antinociceptive effects of uliginosin B (5, 10, 15
and 90 mg/kg, i.p.), morphine (1, 2, 4 and 8 mg/kg, i.p.), amitripty-
line (1, 3, 10 and 30 mg/kg, i.p.) and clonidine (0.03, 0.1, 0.3
and 1 mg/kg, i.p.) were evaluated through the hot-plate assay,
performed as described by Stolz et al. (2012). The results were
expressed as percentages of maximum possible analgesic effect
(%MPE), using the following formula:
%MPE = [(post-drugtreatmentlatency − pre-drugtreatmentlatency)
/(cut-ofﬂatency − pre-drugtreatmentlatency)] × 100
where the cut-off latency was  set as 40 s.
Dose – response curves in the hot-plate test were also obtained
for the mixtures of uliginosin B with each analgesic drug (mor-
phine, amitriptyline or clonidine) through a ﬁxed-ratio design
where the two  drugs were co-administered in amounts that keep
the proportions of each constant, using multiples of their indi-
vidual ED50 values, as follows: 1/8:1/8 (uliginosin B 1.46 mg/kg
associated with morphine 0.39 mg/kg or amitriptyline 1.44 mg/kg
or clonidine 0.02 mg/kg); 1/4:1/4 (uliginosin B 2.92 mg/kg asso-
ciated with morphine 0.79 mg/kg, amitriptyline 2.88 mg/kg or
clonidine 0.04 mg/kg); 1/2:1/2 (uliginosin B 5.84 mg/kg asso-
ciated with morphine 1.58 mg/kg, amitriptyline 5.76 mg/kg or
clonidine 0.07 mg/kg); 1:1 (uliginosin B 11.67 mg/kg associated
with morphine 3.15 mg/kg, amitriptyline 11.51 mg/kg or clonidine
0.14 mg/kg).
The drug-induced motor impairments were assessed by the
rotarod test. The animals were treated with the same doses used
in the hot-plate test, starting from the highest effective doses. The
integrity of motor coordination was  established considering the
longest time of permanence and the number of falls in a period of
5 min, using the protocol described elsewhere (Stolz et al., 2012).
The rotarod test was  performed for each mixture at the same doses
used in hot-plate test, starting from the highest doses.
The isobolographic analyses (hot-plate test) were performed
according to the model described for substances with differ-
ent maximum effects as described elsewhere (Tallarida, 2006;
Woolverton et al., 2008). Firstly the values for ED50, maximum
effect (Emax) and Hill coefﬁcient (h) were determined by non-linear
regressions of the dose – response curves (for each drug and mix-
tures), ﬁxing zero as the minimal effect (Emin). These data were used
to calculate the experimental equi-effective doses by the equation:
Ei = (EmaxDh)/(Dh + EDh50)
where Ei is the selected effect level (50% MPE) and D is the equi-
effective dose for this effect level.
The additive line was  calculated using the following equation
(Grabovsky and Tallarida, 2004):
B = b + D /[(E /E )(1 + DhA/ahA ) − 1]1/hBamitriptyline or clonidine) at the level effect (50% MPE); (a, b) pairs
are the doses of drug A and B deﬁning the isobole of additivity; DA
and DB are the ED50 values; EA and EB are the Emax values; hA and
hB are the Hill coefﬁcients for drug A and B, respectively.
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Fig. 2. Analysis of morphine/uliginosin B interaction. (A) Dose – response curves
for  the antinociceptive effect of morphine, uliginosin B and morphine/uliginosin
B  combination in the hot-plate test. Data are presented as mean ± S.E.M. (n = 8 –

































Fig. 3. Analysis of amitriptyline/uliginosin B interaction. (A) Dose – response
curves for the antinociceptive effect of amitriptyline, uliginosin B and amitripty-
line/uliginosin B combination in the hot-plate test. Data are presented as
mean ± S.E.M. (n = 8 – 10 mice/group). (B) Isobolographic analysis of mor-
phine/uliginosin B interaction. The continuous line is the line of additivity,he continuous line is the line of additivity, representing all the additive theoreti-
al  combinations for a 50% effect level. The point () represents the experimental
ombination for a 50% effect level with its 95% CI.
tatistical analysis
The rotarod data were evaluated using two-way repeated meas-
res analysis of variance (ANOVA) followed by the Student –
ewman – Keuls test (Sigma Stat 3.2 software, Jandel Scientiﬁc
orporation®). Differences were considered statistically signiﬁcant
t p < 0.05. The non-linear regression analyses were performed
sing GraphPad Prism® version 4.02. All results were expressed in
ean ± S.E.M or as dose values with their 95% conﬁdence interval
CI).
esults and discussion
The intraperitoneal administration of morphine, uliginosin B
nd mixture of morphine/uliginosin B produced a dose-dependent
ntinociceptive effect in the hot-plate assay (Fig. 2A). The dose-
esponse curves showed that morphine presents higher efﬁcacy
nd potency than uliginosin B (Table 1). The isobologram was  per-
ormed at the experimental doses producing the effect level of 50%
see Table 1). Visual analysis of the isobologram (Fig. 2B) shows
hat the equi-effective dose pair is below the additive curve, at the
hosen effect level (50% of the maximal possible effect), indicating
he occurrence of synergism between morphine and uliginosin B.
his result is in agreement with previous data showing that the
liginosin B does not bind to opioid receptors and does not stimu-
ate the G protein coupled to these receptors (Stolz et al., 2012) so
hat its site of action seems to be different from morphine (opioid
nalgesic), which is compatible with the occurrence of a synergistic
ffect.
The mechanistic basis of the synergistic interaction may  lie in
he intricate interplay between opioid and monoaminergic sys-
ems. We  can speculate that synergism occurs as a result of mutual
nteraction between independent effects of morphine (opioid
eceptors activation) and uliginosin B (activation of monoamin-
rgic system). Indeed, several antidepressants that increase therepresenting all the additive theoretical combinations for a 50% effect level. The
point () represents the experimental combination for a 50% effect level with its
95% CI.
availability of monoamines in the synaptic cleft also exhibit syn-
ergism with morphine (Shen et al., 2013).
Stolz et al. (2012) showed that activation of opioid receptors is
important for the antinociceptive effect of uliginosin B and sug-
gested that this effect could be the result of increased levels of
endogenous endorphins, resulting from the activation of dopami-
nergic pathways. If we consider this a valid hypothesis, this increase
in endorphins activates a subpopulation of opioid receptors which
are not activated by morphine, in a similar manner to that demon-
strated by other authors, when two  opioid drugs have synergistic
effect (Miranda et al., 2013).
The results of the rotarod test (Table 2) evidenced that mor-
phine and uliginosin B, when administered alone, induced a motor
impairment at doses that promoted the maximum antinocicep-
tive effect, in good accordance with the literature (Loram et al.,
2007; Spetea et al., 2010; Stolz et al., 2012). On the other hand,
a combination of morphine and uliginosin B that produced the
maximal antinociceptive effect (morphine 3.17 mg/kg + uliginosin
B 12.35 mg/kg) did not induce motor impairment. This point to
uliginosin B as a potential adjuvant to morphine for treating some
painful conditions where sedation is not desired.
The intraperitoneal administration of amitriptyline, uliginosin
B and mixture of them produced dose-dependent antinociceptive
effects in the hot-plate test (Fig. 3A). The dose – response curves
showed that amitriptyline presents a higher efﬁcacy than uliginosin
B (Table 1); the experimental doses that produced the effect level of
50% (see Table 1) were chosen to perform the isobologram. Visual
analysis of the isobologram (Fig. 3B) shows that the equi-effective
dose pair is superposed to the theoretical additive curve, indicating
the occurrence of additivity between amitriptyline and uliginosin B.
The additive effect between amitriptyline and uliginosin B is in line
with the fact that both drugs seem to act by enhancing the avail-
ability of monoamines in the synaptic cleft (Brunton et al., 2007;
Stein et al., 2012).
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Table  1
Effective doses for the antinociceptive effect of uliginosin B, morphine, amitriptyline and clonidine alone and in combination in the hot-plate test. The ED50 and the doses
producing 50% of the maximum possible analgesic effect (D50%) with their respective maximum effect (Emax) and Hill coefﬁcient (h) were determined by non-linear regression.
Doses results are expressed as mean with their 95% conﬁdence interval (CI).
Treatments ED50 (95% CI) D50% (95% CI) Emax ± S.E.M. h
Uliginosin B 11.67 (9.03 – 15.07) 24.51 (6.62 – 32.14) 52.52 ± 6.45 4.025
Morphine 3.15 (2.28 – 4.35) 3.26 (2.33 – 4.55) 95.38 ± 12.68 2.950
Amitriptyline 11.51 (2.22 – 59.70) 6.84 (1.86 – 25.06) 136.50 ± 48.06 1.054
Clonidine 0.14 (0.06 – 0.32) 0.13 (0.06 – 0.28) 105.60 ± 18.50 1.430
Morphine/Uliginosin B 5.39 (4.08 – 7.11) 5.44 (4.10 – 7.21) 97.80 ± 10.44 2.993
Amitriptyline/Uliginosin B 7.50 (2.57 – 21.88) 9.29 (2.61 – 32.89) 85.47 ± 35.71 1.615
Clonidine/Uliginosin B 8.03 (2.19 – 29.44) 6.16 (2.12 – 17.86) 133.10 ± 68.15 1.907
Table 2
Effect of uliginosin B, morphine, amitriptyline and clonidine, alone and in combination, on the number of falls and permanence time in the rotarod test. Results are expressed
as  mean ± S.E.M.
Treatments (mg/kg, i.p.) Fall number Higher permanence time (s)
T0 T30 T0 T30
Vehicle 0.8 ± 0.3 1.1 ± 0.4 256.6 ± 11.1 251.5 ± 12.3
Uliginosin B 15.00 1.7 ± 0.6 2.6 ± 0.8 211.4 ± 25.6 187.3 ± 26.9
Uliginosin B 90.00 2.1 ± 0.9 23.4 ± 4.5###,*** 230.4 ± 24.4 45.6 ± 14.9###,***
Morphine 4.00 1.9 ± 0.5 1.0 ± 0.5 208.8 ± 25.6 253.2 ± 23.2
Morphine 8.00 0.6 ± 0.2 9.8 ± 2.4###,*** 258.9 ± 18.7 131.9 ± 27.4###,**
Amitriptyline 10.00 0.6 ± 0.3 2.2 ± 0.8 250.6 ± 16.6 215.6 ± 26.4
Amitriptyline 30.00 1.2 ± 0.6 64.8 ± 3.2###,*** 258.9 ± 18.7 131.9 ± 27.4###,***
Clonidine 0.30 1.5 ± 0.6 0.6 ± 0.4 244.9 ± 21.3 245.5 ± 30.6
Clonidine 1.00 2.5 ± 1.2 18.6 ± 2.0###,*** 224.7 ± 23.4 31.8 ± 6.4###,***
Morphine 3.17/Uliginosin B 12.35 1.0 ± 0.3 1.0 ± 0.4 253.7 ± 21.8 244.0 ± 25.0
Amitriptyline 5.51/Uliginosin B 6.18 1.9 ± 0.9 1.3 ± 0.9 243.1 ± 22.0 251.8 ± 21.8
Amitriptyline 11.01/Uliginosin B 12.35 1.9 ± 0.8 20.0 ± 3.8###,*** 223.3 ± 25.8 35.1 ± 9.0###,***
Clonidine 0.16/Uliginosin B 12.35 1.7 ± 0.7 1.2 ± 0.4 232.4 ± 19.7 233.7 ± 25.0
### Two way repeated measures ANOVA followed by Student – Newmann – Keuls: p < 0.001 difference in relation to T0 exposition.
***
 p < 0.001 difference in relation to the same treatment at a lower dose.




























Fig. 4. Analysis of clonidine/uliginosin B interaction. (A) Dose – response curves
for the antinociceptive effect of clonidine, uliginosin B and clonidine/uliginosin
B combination in the hot-plate test. Data are presented as mean ± S.E.M. (n = 8-
10  mice/group). (B) Isobolographic analysis of morphine/uliginosin B interaction.
The continuous line is the line of additivity, representing all the additive theoreti-Two way repeated measures ANOVA followed by Student – Newmann – Keuls:
** Two way repeated measures ANOVA followed by Student – Newmann – Keuls:
The results of the rotarod assay (Table 2) indicate that both
he substances, when administered alone or in combination,
nduce a motor impairment at doses that promote the maxi-
um  antinociceptive effect, which reafﬁrms the additivity between
hese substances. This group of results strengthens the key role
f monoaminergic pathways to the mechanism of action of
liginosin B.
The intraperitoneal administration of clonidine, uliginosin B and
heir mixture produced a dose-dependent antinociceptive effect in
he hot-plate assay (Fig. 4A). The dose – response curves showed
hat clonidine presents higher efﬁcacy and potency than uliginosin
 (Table 1); the experimental doses that produced the effect level
f 50% (see Table 1) was chosen to perform the isobologram. In this
ase, the equi-effective dose pair is superposed the additive curve
Fig. 4B), indicating the occurrence of additivity effect between
lonidine and uliginosin B.
As uliginosin B appears to act by increasing the availability of
onoamines, including noradrenaline (Stein et al., 2012), an oppo-
ite effect to clonidine could be expected. The mechanism of action
f clonidine is not fully elucidated although it is known that it is an
gonist at the 2-adrenergic and imidazoline receptors, suppress-
ng the release of noradrenaline in postganglionic sympathetic
erves and that it decreases plasma concentration of noradrenaline
Brunton et al., 2007). In fact, results about the nature of clonidine
nteraction with monoamine reuptake inhibitors are controversial.
ifferent studies reported that the combination of clonidine with
onoamine reuptake inhibitors produces synergistic, additive orntagonistic effects (Eisenach and Gebhart, 1995; Hardy and Wells,
988; Nikolic et al., 2009).
The rotarod data depicted in Table 2 show that the combina-
ion between clonidine and uliginosin B did not impair the motor
cal  combinations for a 35% effect level. The point () represents the experimental
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oordination of mice at the dose that present the maximum efﬁcacy
n the hot-plate assay contrary to what occurs when administered
lone, suggesting that the additive effect does not take place in this
ehavioral parameter.
In summary, the results so far reinforce the hypothesis that the
onoaminergic pathways underlie the action of uliginosin B and
oint to this natural phloroglucinol derivative as a potential drug
o reduce doses of morphine in clinical practice.
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